Asunto(s)
Médula Ósea/patología , COVID-19/complicaciones , Muerte Súbita/etiología , Errores Diagnósticos , Hematoma Subdural/etiología , Leucemia Mieloide Aguda/diagnóstico , Leucemia Promielocítica Aguda/diagnóstico , Proteínas Nucleares/análisis , SARS-CoV-2/aislamiento & purificación , Biomarcadores de Tumor/análisis , COVID-19/sangre , Proteínas de Unión al ADN/análisis , Muerte Súbita/patología , Dioxigenasas , Coagulación Intravascular Diseminada/etiología , Reacciones Falso Negativas , Resultado Fatal , Humanos , Isocitrato Deshidrogenasa/análisis , Leucemia Mieloide Aguda/genética , Pulmón/virología , Masculino , Persona de Mediana Edad , Nasofaringe/virología , Neutropenia/etiología , Nucleofosmina , Proteínas Proto-Oncogénicas/análisis , Trombocitopenia/etiologíaRESUMEN
The new coronavirus SARS-CoV-2, first identified in Wuhan, China in December, 2019, can cause Severe Acute Respiratory Syndrome (SARS) with massive alveolar damage and progressive respiratory failure. We present the relevant autopsy findings of the first patient known to have died from COVID19 pneumonia in Spain, carried out on the 14th of February, 2020, in our hospital (Hospital Arnau de Vilanova-Lliria, Valencia). Histological examination revealed typical changes of diffuse alveolar damage (DAD) in both the exudative and proliferative phase of acute lung injury. Intra-alveolar multinucleated giant cells, smudge cells and vascular thrombosis were present. The diagnosis was confirmed by reverse real-time PCR assay on a throat swab sample taken during the patient's admission. The positive result was reported fifteen days subsequent to autopsy.